Corbus Pharmaceuticals Presents Additional Data from RESOLVE-1 Study in Systemic Sclerosis
09. November 2020 08:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Topline data remain as previously reportedPost-hoc analyses showed lenabasum treatment was associated with a benefit in lung function (forced vital capacity) in subjects on established background...